Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1233

1.

Letter to the Editor. Phase III randomized controlled trials are essential to properly evaluate the role of radiotherapy in WHO grade II meningioma.

Jenkinson MD, Weber DC, Haylock BJ, Sherratt FC, Young B, Weller M, Bulbeck H, Culeddu G, Hughes DA, Brain A, Das K, Preusser M, Francis P, Gamble C.

J Neurosurg. 2018 Aug 17:1-2. doi: 10.3171/2018.6.JNS181418. [Epub ahead of print] No abstract available.

PMID:
30117772
2.

Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial.

van den Bent MJ, Klein M, Smits M, Reijneveld JC, French PJ, Clement P, de Vos FYF, Wick A, Mulholland PJ, Taphoorn MJB, Lewis J, Weller M, Chinot OL, Kros JM, de Heer I, Verschuere T, Coens C, Golfinopoulos V, Gorlia T, Idbaih A.

Lancet Oncol. 2018 Aug 13. pii: S1470-2045(18)30362-0. doi: 10.1016/S1470-2045(18)30362-0. [Epub ahead of print]

PMID:
30115593
3.

Response Assessment of Meningioma: 1D, 2D and Volumetric Criteria for Treatment Response and Tumor Progression.

Huang RY, Unadkat P, Linda Bi W, George E, Preusser M, McCracken DJ, Keen JR, Read WL, Olson JJ, Seystahl K, Le Rhun E, Roelcke U, Koeppen S, Furtner J, Weller M, Raizer JJ, Schiff D, Wen PY.

Neuro Oncol. 2018 Aug 2. doi: 10.1093/neuonc/noy126. [Epub ahead of print]

PMID:
30085283
4.

A tissue-based draft map of the murine MHC class I immunopeptidome.

Schuster H, Shao W, Weiss T, Pedrioli PGA, Roth P, Weller M, Campbell DS, Deutsch EW, Moritz RL, Planz O, Rammensee HG, Aebersold R, Caron E.

Sci Data. 2018 Aug 7;5:180157. doi: 10.1038/sdata.2018.157.

5.

Resonance signatures in the body-frame valence photoionization of CF4.

Larsen KA, Trevisan CS, Lucchese RR, Heck S, Iskandar W, Champenois E, Gatton A, Moshammer R, Strom R, Severt T, Jochim B, Reedy D, Weller M, Landers AL, Williams JB, Ben-Itzhak I, Dörner R, Slaughter D, McCurdy CW, Weber T, Rescigno TN.

Phys Chem Chem Phys. 2018 Aug 15;20(32):21075-21084. doi: 10.1039/c8cp03637c.

PMID:
30074041
6.

Investigations of the Copper Peptide Hepcidin-25 by LC-MS/MS and NMR.

Abbas IM, Vranic M, Hoffmann H, El-Khatib AH, Montes-Bayón M, Möller HM, Weller MG.

Int J Mol Sci. 2018 Aug 2;19(8). pii: E2271. doi: 10.3390/ijms19082271.

7.

DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment.

Witt H, Gramatzki D, Hentschel B, Pajtler KW, Felsberg J, Schackert G, Löffler M, Capper D, Sahm F, Sill M, von Deimling A, Kool M, Herrlinger U, Westphal M, Pietsch T, Reifenberger G, Pfister SM, Tonn JC, Weller M; German Glioma Network.

Neuro Oncol. 2018 Jul 24. doi: 10.1093/neuonc/noy118. [Epub ahead of print]

PMID:
30053291
8.

Associations of anticoagulant use with outcome in newly diagnosed glioblastoma.

Le Rhun E, Genbrugge E, Stupp R, Chinot OL, Nabors LB, Cloughesy T, Reardon DA, Wick W, Gorlia T, Weller M.

Eur J Cancer. 2018 Jul 20;101:95-104. doi: 10.1016/j.ejca.2018.06.029. [Epub ahead of print]

PMID:
30036741
9.

Glioblastoma quo vadis: Will migration and invasiveness reemerge as therapeutic targets?

Lefranc F, Le Rhun E, Kiss R, Weller M.

Cancer Treat Rev. 2018 Jul;68:145-154. doi: 10.1016/j.ctrv.2018.06.017. Epub 2018 Jun 26. Review.

10.

Unfavorable Structural and Functional Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis.

Jelcic I, Hanson JVM, Lukas S, Weber KP, Landau K, Pless M, Reindl M, Weller M, Martin R, Lutterotti A, Schippling S.

J Neuroophthalmol. 2018 Jul 13. doi: 10.1097/WNO.0000000000000669. [Epub ahead of print]

PMID:
30015656
11.

Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development.

Binder ZA, Thorne AH, Bakas S, Wileyto EP, Bilello M, Akbari H, Rathore S, Ha SM, Zhang L, Ferguson CJ, Dahiya S, Bi WL, Reardon DA, Idbaih A, Felsberg J, Hentschel B, Weller M, Bagley SJ, Morrissette JJD, Nasrallah MP, Ma J, Zanca C, Scott AM, Orellana L, Davatzikos C, Furnari FB, O'Rourke DM.

Cancer Cell. 2018 Jul 9;34(1):163-177.e7. doi: 10.1016/j.ccell.2018.06.006.

PMID:
29990498
12.

Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate.

Bunse L, Pusch S, Bunse T, Sahm F, Sanghvi K, Friedrich M, Alansary D, Sonner JK, Green E, Deumelandt K, Kilian M, Neftel C, Uhlig S, Kessler T, von Landenberg A, Berghoff AS, Marsh K, Steadman M, Zhu D, Nicolay B, Wiestler B, Breckwoldt MO, Al-Ali R, Karcher-Bausch S, Bozza M, Oezen I, Kramer M, Meyer J, Habel A, Eisel J, Poschet G, Weller M, Preusser M, Nadji-Ohl M, Thon N, Burger MC, Harter PN, Ratliff M, Harbottle R, Benner A, Schrimpf D, Okun J, Herold-Mende C, Turcan S, Kaulfuss S, Hess-Stumpp H, Bieback K, Cahill DP, Plate KH, Hänggi D, Dorsch M, Suvà ML, Niemeyer BA, von Deimling A, Wick W, Platten M.

Nat Med. 2018 Aug;24(8):1192-1203. doi: 10.1038/s41591-018-0095-6. Epub 2018 Jul 9.

PMID:
29988124
13.

Copy number profiling across glioblastoma populations has implications for clinical trial design.

Cimino PJ, McFerrin L, Wirsching HG, Arora S, Bolouri H, Rabadan R, Weller M, Holland EC.

Neuro Oncol. 2018 Jul 2. doi: 10.1093/neuonc/noy108. [Epub ahead of print]

PMID:
29982740
14.

On the way to precision formulation additives: 2D-screening to select solubilizers with tailored host and release capabilities.

Remmler D, Schwaar T, Pickhardt M, Donth C, Mandelkow E, Weller MG, Börner HG.

J Control Release. 2018 Sep 10;285:96-105. doi: 10.1016/j.jconrel.2018.06.032. Epub 2018 Jun 28.

PMID:
29964137
15.

In search of cerebrospinal fluid biomarkers of fatigue in multiple sclerosis: A proteomics study.

Valko PO, Roschitzki B, Faigle W, Grossmann J, Panse C, Biro P, Dambach M, Spahn DR, Weller M, Martin R, Baumann CR.

J Sleep Res. 2018 Jul 1:e12721. doi: 10.1111/jsr.12721. [Epub ahead of print]

PMID:
29961995
16.

Corrigendum: Computer-assisted quantification of motile and invasive capabilities of cancer cells.

Kumar KS, Pillong M, Kunze J, Burghardt I, Weller M, Grotzer MA, Schneider G, Baumgartner M.

Sci Rep. 2018 Jul 2;8:46996. doi: 10.1038/srep46996.

17.

Epidermal growth factor receptor and ligand family expression and activity in glioblastoma.

von Achenbach C, Weller M, Szabo E.

J Neurochem. 2018 Jun 28. doi: 10.1111/jnc.14538. [Epub ahead of print]

PMID:
29953622
18.

Tumor-treating fields: time for demystification.

Weller M.

Ann Oncol. 2018 Jun 14. doi: 10.1093/annonc/mdy220. [Epub ahead of print] No abstract available.

PMID:
29905756
19.

Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group.

Arvold ND, Armstrong TS, Warren KE, Chang SM, DeAngelis LM, Blakeley J, Chamberlain MC, Dunbar E, Loong HH, Macdonald DR, Reardon DA, Vogelbaum MA, Yuan Y, Weller M, van den Bent M, Wen PY.

Neuro Oncol. 2018 Jun 18;20(7):897-906. doi: 10.1093/neuonc/noy056.

PMID:
29788429
20.

Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.

Shirahata M, Ono T, Stichel D, Schrimpf D, Reuss DE, Sahm F, Koelsche C, Wefers A, Reinhardt A, Huang K, Sievers P, Shimizu H, Nanjo H, Kobayashi Y, Miyake Y, Suzuki T, Adachi JI, Mishima K, Sasaki A, Nishikawa R, Bewerunge-Hudler M, Ryzhova M, Absalyamova O, Golanov A, Sinn P, Platten M, Jungk C, Winkler F, Wick A, Hänggi D, Unterberg A, Pfister SM, Jones DTW, van den Bent M, Hegi M, French P, Baumert BG, Stupp R, Gorlia T, Weller M, Capper D, Korshunov A, Herold-Mende C, Wick W, Louis DN, von Deimling A.

Acta Neuropathol. 2018 Jul;136(1):153-166. doi: 10.1007/s00401-018-1849-4. Epub 2018 Apr 23.

PMID:
29687258
21.

[Basic principles of diagnosis and treatment of gliomas].

Wirsching HG, Weiss T, Roth P, Weller M.

Nervenarzt. 2018 Jun;89(6):692-698. doi: 10.1007/s00115-018-0519-z. Review. German.

PMID:
29679127
22.

Diagnostic value of 18F-fluordesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site.

Wolpert F, Weller M, Berghoff AS, Rushing E, Füreder LM, Petyt G, Leske H, Andratschke N, Regli L, Neidert MC, Stupp R, Stahel R, Dummer R, Frauenfelder T, Roth P, Reyns N, Kaufmann PA, Preusser M, Le Rhun E.

Eur J Cancer. 2018 Jun;96:64-72. doi: 10.1016/j.ejca.2018.03.010. Epub 2018 Apr 17.

PMID:
29677642
23.

Improved LC-MS/MS method for the quantification of hepcidin-25 in clinical samples.

Abbas IM, Hoffmann H, Montes-Bayón M, Weller MG.

Anal Bioanal Chem. 2018 Jun;410(16):3835-3846. doi: 10.1007/s00216-018-1056-0. Epub 2018 Apr 18.

PMID:
29666914
24.

Next generation neuro-oncology.

Weller M.

Eur J Cancer. 2018 Jun;96:1-5. doi: 10.1016/j.ejca.2018.03.016. Epub 2018 Apr 12. Review.

PMID:
29656021
25.

Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial.

Wirsching HG, Tabatabai G, Roelcke U, Hottinger AF, Jörger F, Schmid A, Plasswilm L, Schrimpf D, Mancao C, Capper D, Conen K, Hundsberger T, Caparrotti F, von Moos R, Riklin C, Felsberg J, Roth P, Jones DTW, Pfister S, Rushing EJ, Abrey L, Reifenberger G, Held L, von Deimling A, Ochsenbein A, Weller M.

Ann Oncol. 2018 Jun 1;29(6):1423-1430. doi: 10.1093/annonc/mdy120.

PMID:
29648580
26.

Current state of immunotherapy for glioblastoma.

Lim M, Xia Y, Bettegowda C, Weller M.

Nat Rev Clin Oncol. 2018 Jul;15(7):422-442. doi: 10.1038/s41571-018-0003-5. Review.

PMID:
29643471
27.

Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence.

Katz LM, Hielscher T, Liechty B, Silverman J, Zagzag D, Sen R, Wu P, Golfinos JG, Reuss D, Neidert MC, Wirsching HG, Baumgarten P, Herold-Mende C, Wick W, Harter PN, Weller M, von Deimling A, Snuderl M, Sen C, Sahm F.

Acta Neuropathol. 2018 Jun;135(6):955-963. doi: 10.1007/s00401-018-1844-9. Epub 2018 Apr 7.

PMID:
29627952
28.

Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study.

Gramatzki D, Roth P, Rushing EJ, Weller J, Andratschke N, Hofer S, Korol D, Regli L, Pangalu A, Pless M, Oberle J, Bernays R, Moch H, Rohrmann S, Weller M.

Ann Oncol. 2018 Jun 1;29(6):1431-1436. doi: 10.1093/annonc/mdy106.

PMID:
29617713
29.

Online immunocapture ICP-MS for the determination of the metalloprotein ceruloplasmin in human serum.

Bernevic B, El-Khatib AH, Jakubowski N, Weller MG.

BMC Res Notes. 2018 Apr 2;11(1):213. doi: 10.1186/s13104-018-3324-7.

30.

Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations.

Reinhardt A, Stichel D, Schrimpf D, Sahm F, Korshunov A, Reuss DE, Koelsche C, Huang K, Wefers AK, Hovestadt V, Sill M, Gramatzki D, Felsberg J, Reifenberger G, Koch A, Thomale UW, Becker A, Hans VH, Prinz M, Staszewski O, Acker T, Dohmen H, Hartmann C, Mueller W, Tuffaha MSA, Paulus W, Heß K, Brokinkel B, Schittenhelm J, Monoranu CM, Kessler AF, Loehr M, Buslei R, Deckert M, Mawrin C, Kohlhof P, Hewer E, Olar A, Rodriguez FJ, Giannini C, NageswaraRao AA, Tabori U, Nunes NM, Weller M, Pohl U, Jaunmuktane Z, Brandner S, Unterberg A, Hänggi D, Platten M, Pfister SM, Wick W, Herold-Mende C, Jones DTW, von Deimling A, Capper D.

Acta Neuropathol. 2018 Aug;136(2):273-291. doi: 10.1007/s00401-018-1837-8. Epub 2018 Mar 21.

PMID:
29564591
31.

Profiling walking dysfunction in multiple sclerosis: characterisation, classification and progression over time.

Filli L, Sutter T, Easthope CS, Killeen T, Meyer C, Reuter K, Lörincz L, Bolliger M, Weller M, Curt A, Straumann D, Linnebank M, Zörner B.

Sci Rep. 2018 Mar 21;8(1):4984. doi: 10.1038/s41598-018-22676-0.

32.

The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy.

Neidert MC, Kowalewski DJ, Silginer M, Kapolou K, Backert L, Freudenmann LK, Peper JK, Marcu A, Wang SS, Walz JS, Wolpert F, Rammensee HG, Henschler R, Lamszus K, Westphal M, Roth P, Regli L, Stevanović S, Weller M, Eisele G.

Acta Neuropathol. 2018 Jun;135(6):923-938. doi: 10.1007/s00401-018-1836-9. Epub 2018 Mar 20.

PMID:
29557506
33.

DNA methylation-based classification of central nervous system tumours.

Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D, Koelsche C, Sahm F, Chavez L, Reuss DE, Kratz A, Wefers AK, Huang K, Pajtler KW, Schweizer L, Stichel D, Olar A, Engel NW, Lindenberg K, Harter PN, Braczynski AK, Plate KH, Dohmen H, Garvalov BK, Coras R, Hölsken A, Hewer E, Bewerunge-Hudler M, Schick M, Fischer R, Beschorner R, Schittenhelm J, Staszewski O, Wani K, Varlet P, Pages M, Temming P, Lohmann D, Selt F, Witt H, Milde T, Witt O, Aronica E, Giangaspero F, Rushing E, Scheurlen W, Geisenberger C, Rodriguez FJ, Becker A, Preusser M, Haberler C, Bjerkvig R, Cryan J, Farrell M, Deckert M, Hench J, Frank S, Serrano J, Kannan K, Tsirigos A, Brück W, Hofer S, Brehmer S, Seiz-Rosenhagen M, Hänggi D, Hans V, Rozsnoki S, Hansford JR, Kohlhof P, Kristensen BW, Lechner M, Lopes B, Mawrin C, Ketter R, Kulozik A, Khatib Z, Heppner F, Koch A, Jouvet A, Keohane C, Mühleisen H, Mueller W, Pohl U, Prinz M, Benner A, Zapatka M, Gottardo NG, Driever PH, Kramm CM, Müller HL, Rutkowski S, von Hoff K, Frühwald MC, Gnekow A, Fleischhack G, Tippelt S, Calaminus G, Monoranu CM, Perry A, Jones C, Jacques TS, Radlwimmer B, Gessi M, Pietsch T, Schramm J, Schackert G, Westphal M, Reifenberger G, Wesseling P, Weller M, Collins VP, Blümcke I, Bendszus M, Debus J, Huang A, Jabado N, Northcott PA, Paulus W, Gajjar A, Robinson GW, Taylor MD, Jaunmuktane Z, Ryzhova M, Platten M, Unterberg A, Wick W, Karajannis MA, Mittelbronn M, Acker T, Hartmann C, Aldape K, Schüller U, Buslei R, Lichter P, Kool M, Herold-Mende C, Ellison DW, Hasselblatt M, Snuderl M, Brandner S, Korshunov A, von Deimling A, Pfister SM.

Nature. 2018 Mar 22;555(7697):469-474. doi: 10.1038/nature26000. Epub 2018 Mar 14.

PMID:
29539639
34.

Working plan for the use of patient-reported outcome measures in adults with brain tumours: a Response Assessment in Neuro-Oncology (RANO) initiative.

Dirven L, Armstrong TS, Blakeley JO, Brown PD, Grant R, Jalali R, Leeper H, Mendoza T, Nayak L, Reijneveld JC, Le Rhun E, Walbert T, Weller M, Wen PY, Taphoorn MJB.

Lancet Oncol. 2018 Mar;19(3):e173-e180. doi: 10.1016/S1470-2045(18)30004-4. Review.

PMID:
29508764
35.

Antitumor Activity of DLX1008, an Anti-VEGFA Antibody Fragment with Low Picomolar Affinity, in Human Glioma Models.

Szabó E, Phillips DJ, Droste M, Marti A, Kretzschmar T, Shamshiev A, Weller M.

J Pharmacol Exp Ther. 2018 May;365(2):422-429. doi: 10.1124/jpet.117.246249. Epub 2018 Mar 5.

PMID:
29507055
36.

Transcriptional control of O6 -methylguanine DNA methyltransferase expression and temozolomide resistance in glioblastoma.

Happold C, Stojcheva N, Silginer M, Weiss T, Roth P, Reifenberger G, Weller M.

J Neurochem. 2018 Mar;144(6):780-790. doi: 10.1111/jnc.14326.

PMID:
29480969
37.

Ten Basic Rules of Antibody Validation.

Weller MG.

Anal Chem Insights. 2018 Feb 8;13:1177390118757462. doi: 10.1177/1177390118757462. eCollection 2018. Review.

38.

Linking dendroecology and association genetics in natural populations: Stress responses archived in tree rings associate with SNP genotypes in silver fir (Abies alba Mill.).

Heer K, Behringer D, Piermattei A, Bässler C, Brandl R, Fady B, Jehl H, Liepelt S, Lorch S, Piotti A, Vendramin GG, Weller M, Ziegenhagen B, Büntgen U, Opgenoorth L.

Mol Ecol. 2018 Mar;27(6):1428-1438. doi: 10.1111/mec.14538. Epub 2018 Apr 2.

PMID:
29443422
39.

Synthesis, structure and optoelectronic properties of hybrid iodobismuthate & iodoantimonate semiconducting materials.

Dennington AJ, Weller MT.

Dalton Trans. 2018 Mar 6;47(10):3469-3484. doi: 10.1039/c7dt04280a.

PMID:
29431780
40.

Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma?

Happold C, Gorlia T, Nabors LB, Erridge SC, Reardon DA, Hicking C, Picard M, Stupp R, Weller M; EORTC Brain Tumor Group and on behalf of the CENTRIC and CORE Clinical Trial Groups.

J Neurooncol. 2018 May;138(1):163-171. doi: 10.1007/s11060-018-2786-8. Epub 2018 Feb 8.

PMID:
29423540
41.

Safety of a High-Dose Tranexamic Acid Protocol in Complex Adult Spinal Deformity: Analysis of 100 Consecutive Cases.

Lin JD, Lenke LG, Shillingford JN, Laratta JL, Tan LA, Fischer CR, Weller MA, Lehman RA Jr.

Spine Deform. 2018 Mar - Apr;6(2):189-194. doi: 10.1016/j.jspd.2017.08.007. Epub 2017 Nov 2.

PMID:
29413743
42.

Where does O6 -methylguanine DNA methyltransferase promoter methylation assessment place temozolomide in the future standards of care for glioblastoma?

Weller M.

Cancer. 2018 Apr 1;124(7):1316-1318. doi: 10.1002/cncr.31244. Epub 2018 Jan 30. No abstract available.

PMID:
29381186
43.

Increased Risk of Penile Cancer among Men Working in Agriculture

Júnior PFM, Silva EHV, Moura KL, de Aquino YF, Weller M.

Asian Pac J Cancer Prev. 2018 Jan 27;19(1):237-241.

44.

Zinc Tantalum Oxynitride (ZnTaO₂N) Photoanode Modified with Cobalt Phosphate Layers for the Photoelectrochemical Oxidation of Alkali Water.

Arunachalam P, Shaddad MN, Ghanem MA, Al-Mayouf AM, Weller MT.

Nanomaterials (Basel). 2018 Jan 18;8(1). pii: E48. doi: 10.3390/nano8010048.

45.

Calcification of the iliac arteries: a marker for leakage risk in rectal anastomosis-a blinded clinical trial.

Pochhammer J, Tröster F, Blumenstock G, Closset J, Lang S, Weller MP, Schäffer M.

Int J Colorectal Dis. 2018 Feb;33(2):163-170. doi: 10.1007/s00384-017-2949-7. Epub 2017 Dec 22.

PMID:
29273883
46.

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.

Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran D, Brem S, Hottinger A, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Bruna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z.

JAMA. 2017 Dec 19;318(23):2306-2316. doi: 10.1001/jama.2017.18718. Erratum in: JAMA. 2018 May 1;319(17):1824.

47.

Negative control of the HGF/c-MET pathway by TGF-β: a new look at the regulation of stemness in glioblastoma.

Papa E, Weller M, Weiss T, Ventura E, Burghardt I, Szabó E.

Cell Death Dis. 2017 Dec 13;8(12):3210. doi: 10.1038/s41419-017-0051-2.

48.

NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma.

Weiss T, Weller M, Guckenberger M, Sentman CL, Roth P.

Cancer Res. 2018 Feb 15;78(4):1031-1043. doi: 10.1158/0008-5472.CAN-17-1788. Epub 2017 Dec 8.

PMID:
29222400
49.

Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - Authors' reply.

Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, Drappatz J, O'Rourke DM, Wong M, Hamilton MG, Finocchiaro G, Perry J, Wick W, Green J, He Y, Turner CD, Yellin MJ, Keler T, Davis TA, Stupp R, Sampson JH.

Lancet Oncol. 2017 Dec;18(12):e709-e710. doi: 10.1016/S1470-2045(17)30856-2. No abstract available.

PMID:
29208433
50.

Preparation of PEGylated liposomes incorporating lipophilic lomeguatrib derivatives for the sensitization of chemo-resistant gliomas.

Signorell RD, Papachristodoulou A, Xiao J, Arpagaus B, Casalini T, Grandjean J, Thamm J, Steiniger F, Luciani P, Brambilla D, Werner B, Martin E, Weller M, Roth P, Leroux JC.

Int J Pharm. 2018 Jan 30;536(1):388-396. doi: 10.1016/j.ijpharm.2017.11.070. Epub 2017 Dec 2.

PMID:
29198811

Supplemental Content

Loading ...
Support Center